Organizing residental purchasing groups & building.
Suprin ended 2025 with earnings back in positive territory and a broad project platform, but the year was still funded in practice by the debt market and the banking system. The 2026 test is whether receivables, inventory, and Migdalei Atid start releasing real cash.
Series C did not rescue Suprin from a broken debt structure. It widened a structure that already relied increasingly on the debt market. On the audited 2025 numbers, covenant room still looks comfortable, but bondholder protection depends on equity and execution rather than on c…
Migdalei Atid already dominates Suprin's purchase-group economics and balance-sheet exposure through about NIS 91.7 million of project receivables, but the recurring-income layer the company wants to build still has no current NOI from this project, so the real test remains exec…
Suprin's 2025 profit-to-cash gap was mainly a sequencing problem, not an absence of profit. Revenue was recognized, but cash got stuck in Migdalei Atid receivables, interim reimbursements advanced for purchase-group projects, and a land-inventory build led by Yoseftal.
